Gilead Sciences Inc (GILD)

61.210
+0.120(+0.20%)
  • Volume:
    0
  • Bid/Ask:
    64.960/66.780
  • Day's Range:
    60.570 - 61.210
High dividend Yield

GILD Overview

Prev. Close
48.08
Day's Range
60.57-61.21
Revenue
27.52B
Open
60.57
52 wk Range
52.24-65.09
EPS
3.3
Volume
0
Market Cap
76.91B
Dividend (Yield)
2.92
(4.65%)
Average Volume (3m)
125
P/E Ratio
19.30
Beta
0.35
1-Year Change
1.27%
Shares Outstanding
1,253,367,394
Next Earnings Date
-
What is your sentiment on Gilead?
or
Market is currently closed. Voting is open during market hours.

Gilead Sciences Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Gilead Sciences Inc Analysis

Gilead Sciences Inc Company Profile

Gilead Sciences Inc Company Profile

Employees
14400
  • Type:Equity
  • Market:Austria
  • ISIN:US3755581036

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases includes Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. It sells and distributes its products in the United States through the wholesale channel. It operates in more than 35 countries worldwide.

Read More

Technical Summary

Type
Daily
Weekly
Monthly
Moving AveragesStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyBuy
SummaryStrong BuyStrong BuyStrong Buy
  • Good job GILD. bullish move forward
    0
    • Kite, a unit of Gilead Sciences (GILD),has announced that theFDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults...
      1
      • Up Again
        0
        • Time to load up before the big rise coming next week
          3
          • Classic pump n’ dump. What a shambles
            1
            • Will reach above 95
              5
              • when? hahah
                0
            • Good time to accumulate.
              1
              • Gilead will be supplying remdesivir to 127 countries starting next week! Also backed by big government organisations including donald trump. Good investmenr
                2
                • High chance to be trading above 90, good long stock
                  4
                  • By Deena Beasley(Reuters) - More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences Inc., according to new data based on patient observation.The analysis, published on Friday by the New England Journal of Medicine, does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included -- in one case because of a dosing error.
                    3